Q-omics provides the consensus-scored RPL35AP33 profile across patient tissues and cancer cell-line models. RPL35AP33 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RPL35AP33 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, RPL35AP33 RNA expression shows 4,855 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, HNSC, and STAD as cancer lineages where RPL35AP33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL35AP33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL35AP33 survival associations across molecular data types. RPL35AP33 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL35AP33 RNA expression–survival associations across cancer types. High RPL35AP33 expression shows unfavorable associations in UCEC, KIRC, ACC, TGCT, THYM and MESO. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for RPL35AP33 RNA expression.
This table summarizes RPL35AP33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL35AP33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL35AP33 shows lower tumor expression in KIRP and THCA and higher tumor expression in HNSC, COAD and KIRC. The HNSC box plot shows higher RPL35AP33 RNA expression in tumor versus normal tissue (log2 FC = +0.130, t-test p = .003).
This table shows molecular features associated with RPL35AP33 in patient tissues and cancer cell lines. In patient samples, RPL35AP33 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
